Schizophrenia Drug Market & Pipeline Insight is a new market research publication announced by Reportstack. Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could possibly be affected by this disease. There have been rare cases of young children and adolescents also being affected. Overall, in most cases, the development of schizophrenia in earlier stages implies that the disease is very severe. Additionally, it has also been observed that schizophrenia is more severe in men than in women.
Though schizophrenia has been in the realm of research for over a century, the actual cause of the disorder still remains unknown. Pharmacological treatments have been in wide use for many years. However, there is hardly any evidence that these treatments have significantly improved outcomes for most people with schizophrenia. The pharmaceutical companies in this market are currently facing and are expected to continue to face stiff competition from many generic atypical antipsychotics. The major target of differentiating the products through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential have become the main focus of the pharma companies in this market.
The future years are likely to witness a shift in the way in which this disease is perceived. With schizophrenia being considered as a neuro developmental disorder with psychosis as a late stage of illness, it is likely that the current unsatisfactory outcomes could change. Such new ideas of looking into schizophrenia as a neuro developmental disorder, which is substantially different from the way it has been treated previously, offers much potential for future prevention and cure over the next two decades.
“Schizophrenia Drug Market & Pipeline Insight” Report Highlights:
• Schizophrenia Drug Market Overview
• Marketed Drug Profiles & Patent Analysis
• Clinical Trial Insight by Phase & Country
• Drug in Clinical Development Phase: 143
• Majority Therapies in Preclinical Phase: 65
• Marketed Schizophrenia Drugs: 16
• Suspended & Discontinued Drug Profiles: 163
• Competitive Landscape
Abbott Laboratories, Addex Pharmaceuticals, Astellas Pharma, Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck
To view the table of contents and know more details please visit Schizophrenia Drug Market & Pipeline Insight.